830results about "Radioactive preparation forms" patented technology

A bioabsorbable brachytherapy device includes a tubular housing with sealed ends and an enclosed radioactive material. The radioactive material includes a radioisotope, such as palladium-103 or iodine-125. The tubular housing is made from a biocompatible and bioabsorbable polymeric material, and is sealed by means such as heat welding or solvent fixing. The device may further include a radiopaque medium and one or more therapeutic drugs.

The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent.

Cluster clearing agents (CCAs) and the use thereof are discussed. CCAs are composed of a hepatic clearance directing moiety which directs the biodistribution of a CCA-containing construct to hepatic clearance; and a binding moiety which mediates binding of the CCA to a compound for which rapid hepatic clearance is desired.

Disclosed are biocompatible magnetic nanoparticle compositions for various therapeutic or biological applications, and methods related thereto. Specifically, the present invention pertains to magnetic nanoparticle compositions prepared via high-pressure homogenization processes that include a turbulent flow zone. The methods of production may involve a two-step or a one-step process. The disclosed magnetic nanoparticle compositions may be useful in the treatment of the body, body part, tissue, cell, or body fluid of a subject for a variety of indications. The disclosed magnetic nanoparticle compositions may also be useful in the fixation, separation, transportation, marking or coding of targets, or energy transformation processes.

In certain embodiments this invention provides a nanoparticle-based technology platform for multimodal in vivo imaging and therapy. The nanoparticle-based probes detects diseased cells by MRI, PET or deep tissue Near Infrared (NIR) imaging, and are capable of detecting diseased cells with greater sensitivity than is possible with existing technologies. The probes also target molecules that localize to normal or diseased cells, and initiates apoptosis of diseased cells.

A method and apparatus of dispensing a radiopharmaceutical wherein a source of flushing fluid is connected to a first port of a fluid delivery set; a pressurizing unit of a powered injector system (including a powered injector and the pressurizing unit) is connected to a second port of the fluid delivery set; air is purged from the fluid delivery set; and, after purging air from the fluid delivery set, a third port of the fluid delivery set is connected to a source of the radiopharmaceutical. A valve system is included to control flow of fluid. A syringe is operatively connected with a powered injector. A radioactive shield encloses the syringe during operation to protect personnel from detrimental effects. A dose calibrator measure the radioactivity in the syringe.

A breath test for determining the rate of metabolism of a drug is described. First, a safe and effective amount of the drug, preferably appropriately labelled and most preferably isotopically-labelled, is administered to a subject. After a suitable time period, the exhaled breath of the subject is analyzed to determine the concentration of a metabolite. The concentration of the metabolite is then used to determine the rate of metabolism of the drug. A breath test kit is also described. Such a breath test kit would include an item or items necessary for performing at least one of the methods of determining the rate of metabolism of a drug in a subject. For example, such a breath test kit could include an isotopically-labelled drug to be administered to the subject.

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides / radiometals or paramagnetic ions may be conjugated to the nanoparticle.

According to an aspect of the invention, injectable polymeric particles are provided that contain a copolymer that contains a hydroxy-acid-based repeat unit selected from a mono(hydroxy acid) unit and a poly(hydroxy acid) unit, an alkyl-ether-based repeat unit selected from a mono(alkyl ether) unit and a poly(alkyl ether) unit, and an acid-based repeat unit selected from a unit comprising multiple carboxylic acid groups and a derivative thereof Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions.

The present invention relates to a diagnostic agent for liver function, comprising a compound labelled with 13C at least at one specific position selected from the group consisting of the following (a) to (f): (a) galactose, glucose or xylose labelled with 13C at least at one specific position or a starch composed of glucose units labelled with 13C at least at one specific position; (b) a polar amino acid, heterocyclic amino acid, isoleucine or valine labelled with 13C at least at one specific position; (c) a carboxylic acid constituting the glycolytic pathway or the citric acid cycle, labelled with 13C at least at one specific position; (d) a fatty acid labelled with 13C at least at one specific position; (e) a glyceride labelled with 13C at least at one specific position; and (f) glycerol labelled with 13C at least at one specific position. According to the present invention, a diagnostic agent for liver function which imposes less physical burden on a subject, can give accurate test result immediately, and can be used safely without side effects is provided. The diagnostic agent of the invention is useful for evaluating the liver function of a subject at the time when the test is carried out.

The invention describes novel dried powders of peptide therapeutic agent useful for producing highly respirable aerosols and the methods for their manufacture. Insulin is the peptide therapeutic agent in the preferred embodiment. The powders of insulin prepared for pulmonary administration are characterized by the peculiar structure and shape of the microparticles that allow the powder to flow and to be easy aerosolized. Typical dry powder of insulin described in this patent show corrugated, nonagglomerated microparticles with a low tapped density. The mean geometric diameter (particle size) ranges between 1.0 and 10.0 micron and the mass median aerodynamic diameter (MMAD) ranges between 1.0 and 4.0 micron. These insulin pulmonary powders exhibit in vitro a very high respirable fraction (>75%).

A method for the detection of fibrin in a source, in particular the in vivo detection of a fibrin in a patient, the method comprising supplying to the source or patient an amount of a detectable reagent comprising a plurality of discrete particles, each of the particles comprising a plurality of layers of carbon and being capable of binding to fibrin; and detecting the presence of the particles in the source. The particles may also comprise a detectable marker encased in said plurality of layers of carbon, the presence of said marker being capable of detection in said source.

A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and / or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.

The present invention provides methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death.

The present invention provides a series of biocompatible, nanoparticulate formulations that are designed to retain and deliver peptides such as anti-angiogenic factors over an extended time course. The nanoparticles can be targeted to a cell or tissue by targeting ligands crosslinked or conjugated to the corona of the nanoparticles. In addition to selective targeting, the nanoparticles also may perform noninvasive imaging using bioluminescence and / or magnetic resonance imaging via a contrast agent in the core of the nanoparticle. Also provided are methods of delivering to and, optionally, imaging of a cell or tissue. Furthermore, methods of producing the nanoparticles in batch or continous mode via simple mixing or micromixing.

The present invention relates to a method for preparing a radioactive film for local radioactive treatment. More particularly, the present invention relates to a method for preparing a radioactive film comprising the steps of; dissolving 0.1˜14.5 weight % of a stable nuclide and 13˜32.5 weight % of a film-forming base for the total amount of a solvent in the solvent; applying a stable nuclide solution on a release paper by a coater and drying; and irradiating a stable nuclide film with neutrons in a nuclear reactor. A method for preparing a radioactive film according to the present invention provides a radioactive film having a uniform distribution of radionuclides and an even thickness. Therefore, the therapeutic efficacy of the radioactive film for selective treatment of a lesion may be maximized by attaching the radioactive film on a patient's skin or a mucous membrane and by direct radioactive radiation.

The present invention provides a drug delivery system for delivery of an agent and a radiopharmaceutical agent. The drug delivery system may specifically target an organ, tissue, cells, extracellular matrix, or intracellular compartment. Typically, the drug delivery system is a particle. Pharmaceutical compositions comprising the inventive particles are also provided. The present invention provides methods of preparing and using the inventive particles and pharmaceutical compositions. The inventive particles are useful in treating and diagnosing a variety of diseases including cancer. The inventive particles are also useful in tracking particles in vivo.

The present invention relates to a nanoparticle comprising self-assembled crosslinked, amphiphilic block copolymers and at least one immobilized dye, wherein the self-assembled, crosslinked, amphiphilic block copolymers comprise a hydrophilic block and a hydrophobic block, wherein the self-assembled, crosslinked, amphiphilic block copolymers are self-assembled to form a core of the nanoparticle comprising a hydrophobic block, wherein the hydrophobic block is derived from at least one pendant multifunctional crosslinked alkoxy silane or amino silane moiety, and an exterior of the nanoparticle comprising a hydrophilic block, and wherein the immobilized dye is immobilized in the core.

In part, the present invention is directed to a system comprising a lapachone or a prodrug thereof and a polymer, such as a biocompatible and optionally biodegradable polymer, methods for treatment using the subject polymer compositions, and methods of making and using the same. In another part, the present invention includes inclusion complexes of a lapachone or a prodrug thereof and a cyclodextrin, preferably a β-cyclodextrin, such as hydroxypropyl β-cyclodextrin, e.g., to improve the solubility of the lapachone or prodrug thereof.

A patient-specific optimally effective radiation dose for administration of a radiopharmaceutical to a patient for treatment of a disease may be established by basing the calculation of the appropriate therapeutic dose on factors such as the desired total body dose, the maximum tolerated dose, the typical clearance profile of the radiopharmaceutical, the patient's mass or maximum effective mass, and the patient-specific residence time of the radiopharmaceutical or an analog in the whole body of the patient. The use of the method allows for treatment of a patient with an appropriate dose which is maximally effective against the disease yet minimally toxic. The determination of a patient-specific therapeutic dose may be assisted by the use of a software program set to the particular parameters of the radiopharmaceutical.

Methods of making coated implantable medical devices are provided. The methods include positioning a first layer comprising a bioactive on at least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to provide a controlled release of the bioactive.

An apparatus is disclosed that forms a basic integrated radiation shield for a PET isotope production system to create a safe environment. The apparatus and the system combine several subsystems to provide a high degree of integration and a nice aesthetic impression. The apparatus contains a cyclotron system and contains integrated target media handling for gas targets and water dispensing systems for water targets. A compartment including first and second additional radiation shields, respectively, that contains additional processing systems. The apparatus forms a closed radiation-proof system by means of a casing formed of four molded sections. A first and second section constitute a main body containing;the cyclotron system and a third and a fourth section constituting a pair of tight doors for encompassing the cyclotron into a sealed radiation shield. The first section additionally contains a Waste Gas Delay Line embedded in its shielding material.

Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and / or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.

The present invention concerns a design for dendritic poly(amino acid) polymer carriers, also known as nonlinear polymers, and their applications. These dendritic poly(amino acid) carriers have multiple functional groups at the polymer surface. In addition, they have heterofunctional groups on the poly(amino acid) side chains for drug or diagnostic agent attachment. They are designed to allow sufficient preservation of the binding affinity of the targeting ligand while conjugating therapeutic or diagnostic agents to the polymers. The present invention also describes methods of production of the polymer carriers and methods for the treatment or diagnosis of diseases employing the polymer carriers. The present invention also includes methods to introduce targeting moieties site-specifically to the end of polymer chains.

A bioabsorbable brachytherapy device includes a tubular housing with sealed ends and an enclosed radioactive material. The radioactive material includes a radioisotope, such as palladium-103 or iodine-125. The tubular housing is made from a biocompatible and bioabsorbable polymeric material, and is sealed by means such as heat welding or solvent fixing. The device may further include a radiopaque medium and one or more therapeutic drugs.

The present invention relates to a process for making a particulate substance. The process comprises providing an emulsion, optionally a microemulsion, comprising droplets dispersed in a continuous liquid phase. At least some of the droplets of the emulsion comprise nuclei. The droplets are then at least partially destabilised to form the particulate substance.

The invention relates to polymer-coated stents, processes for their production and their use for restenosis prevention.

The present invention relates to the formation of surface treated zinc oxide and titania particles, and in particular zinc oxide and titania nanoparticles, with a siloxane star-graft copolymer coating, comprising a looped and / or linear polymeric structure on a star-graft copolymer coating, on a particle surface to control the interfacial surface interactions between the particle and the oil phase of the cosmetic skin formulation.